Results 151 to 160 of about 192,841 (253)

Five-year Outcome of Aflibercept Administration with “Treat and Extend” for Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Iori Wada,1,2 Yuji Oshima,3 Yosuke Fukuda,1 Satomi Shiose,1 Kumiko Kano,1 Keijiro Ishikawa,1 Shintaro Nakao,4 Yoshihiro Kaizu,1,5 Eiichi Hasegawa,1,2 Ram Kannan,6,7 Tatsuro Ishibashi,1 Koh-Hei Sonoda1 1Department of Ophthalmology, Graduate School of ...
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH   +11 more
doaj  

Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration. [PDF]

Clin Ophthalmol
Wada I, Oshima Y, Fukuda Y, Shiose S, Kano K, Ishikawa K, Nakao S, Kaizu Y, Hasegawa E, Kannan R, Ishibashi T, Sonoda KH.   +11 more
europepmc   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration. [PDF]

BMC Ophthalmol
Menghini M, Grimaldi G, Paris A, Bachmann LM, Schmid MK.   +4 more
europepmc   +1 more source

Comparison of 24-month treatment outcomes between as-needed treatment and switching to treat-and-extend in type 3 macular neovascularization. [PDF]

Sci Rep, 2022
Kim JH, Kim JW, Kim CG.
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Treatment Cessation in Patients with Diabetic Maculopathy under Intravitreal Anti-VEGF Therapy Following a Treat-and-Extend Protocol. [PDF]

Ophthalmol Sci
Saucedo L, Pfister IB, Schild C, Garweg JG.   +3 more
europepmc   +1 more source

Palmerston North Interventional Rapid Avastin Treat and Extend (PIRATE) study protocol; meeting the medical retina service needs of our ageing population. [PDF]

BMJ Open Ophthalmol, 2023
Bonnet LA, Singh V, Ah-Chan J.
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema. [PDF]

J Chin Med Assoc, 2022
Sheu SJ, Yang CH, Lai CC, Wu PC, Chen SJ.   +4 more
europepmc   +1 more source